Rob Hill1,2, Andrew C Kruegel3, Jonathan A Javitch4,5, J Robert Lane1,2, Meritxell Canals1,2. 1. Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, UK. 2. Centre of Membrane Proteins and Receptors, Universities of Nottingham and Birmingham, Midlands, UK. 3. Department of Chemistry, Columbia University, New York, New York, USA. 4. Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA. 5. Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York, USA.
Abstract
BACKGROUND AND PURPOSE: Mitragynine, the major alkaloid in Mitragyna speciosa (kratom), is a partial agonist at the μ opioid receptor. CYP3A-dependent oxidation of mitragynine yields the metabolite 7-OH mitragynine, a more efficacious μ receptor agonist. While both mitragynine and 7-OH mitragynine can induce anti-nociception in mice, recent evidence suggests that 7-OH mitragynine formed as a metabolite is sufficient to explain the anti-nociceptive effects of mitragynine. However, the ability of 7-OH mitragynine to induce μ receptor-dependent respiratory depression has not yet been studied. EXPERIMENTAL APPROACH: Respiration was measured in awake, freely moving, male CD-1 mice, using whole body plethysmography. Anti-nociception was measured using the hot plate assay. Morphine, mitragynine, 7-OH mitragynine and the CYP3A inhibitor ketoconazole were administered orally. KEY RESULTS: The respiratory depressant effects of mitragynine showed a ceiling effect, whereby doses higher than 10 mg·kg-1 produced the same level of effect. In contrast, 7-OH mitragynine induced a dose-dependent effect on mouse respiration. At equi-depressant doses, both mitragynine and 7-OH mitragynine induced prolonged anti-nociception. Inhibition of CYP3A reduced mitragynine-induced respiratory depression and anti-nociception without affecting the effects of 7-OH mitragynine. CONCLUSIONS AND IMPLICATIONS: Both the anti-nociceptive effects and the respiratory depressant effects of mitragynine are partly due to its metabolic conversion to 7-OH mitragynine. The limiting rate of conversion of mitragynine into its active metabolite results in a built-in ceiling effect of the mitragynine-induced respiratory depression. These data suggest that such 'metabolic saturation' at high doses may underlie the improved safety profile of mitragynine as an opioid analgesic.
BACKGROUND AND PURPOSE: Mitragynine, the major alkaloid in Mitragyna speciosa (kratom), is a partial agonist at the μ opioid receptor. CYP3A-dependent oxidation of mitragynine yields the metabolite 7-OH mitragynine, a more efficacious μ receptor agonist. While both mitragynine and 7-OH mitragynine can induce anti-nociception in mice, recent evidence suggests that 7-OH mitragynine formed as a metabolite is sufficient to explain the anti-nociceptive effects of mitragynine. However, the ability of 7-OH mitragynine to induce μ receptor-dependent respiratory depression has not yet been studied. EXPERIMENTAL APPROACH: Respiration was measured in awake, freely moving, male CD-1 mice, using whole body plethysmography. Anti-nociception was measured using the hot plate assay. Morphine, mitragynine, 7-OH mitragynine and the CYP3A inhibitor ketoconazole were administered orally. KEY RESULTS: The respiratory depressant effects of mitragynine showed a ceiling effect, whereby doses higher than 10 mg·kg-1 produced the same level of effect. In contrast, 7-OH mitragynine induced a dose-dependent effect on mouse respiration. At equi-depressant doses, both mitragynine and 7-OH mitragynine induced prolonged anti-nociception. Inhibition of CYP3A reduced mitragynine-induced respiratory depression and anti-nociception without affecting the effects of 7-OH mitragynine. CONCLUSIONS AND IMPLICATIONS: Both the anti-nociceptive effects and the respiratory depressant effects of mitragynine are partly due to its metabolic conversion to 7-OH mitragynine. The limiting rate of conversion of mitragynine into its active metabolite results in a built-in ceiling effect of the mitragynine-induced respiratory depression. These data suggest that such 'metabolic saturation' at high doses may underlie the improved safety profile of mitragynine as an opioid analgesic.
Authors: András Váradi; Gina F Marrone; Travis C Palmer; Ankita Narayan; Márton R Szabó; Valerie Le Rouzic; Steven G Grinnell; Joan J Subrath; Evelyn Warner; Sanjay Kalra; Amanda Hunkele; Jeremy Pagirsky; Shainnel O Eans; Jessica M Medina; Jin Xu; Ying-Xian Pan; Attila Borics; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar Journal: J Med Chem Date: 2016-09-02 Impact factor: 7.446
Authors: Soumen Chakraborty; Rajendra Uprety; Samuel T Slocum; Takeshi Irie; Valerie Le Rouzic; Xiaohai Li; Lisa L Wilson; Brittany Scouller; Amy F Alder; Andrew C Kruegel; Michael Ansonoff; Andras Varadi; Shainnel O Eans; Amanda Hunkele; Abdullah Allaoa; Sanjay Kalra; Jin Xu; Ying Xian Pan; John Pintar; Bronwyn M Kivell; Gavril W Pasternak; Michael D Cameron; Jay P McLaughlin; Dalibor Sames; Susruta Majumdar Journal: J Med Chem Date: 2021-11-16 Impact factor: 7.446
Authors: Lauren C Smith; Lucy Lin; Candy S Hwang; Bin Zhou; Diane M Kubitz; Huiying Wang; Kim D Janda Journal: Chem Res Toxicol Date: 2018-11-16 Impact factor: 3.739
Authors: Kristine R Crews; Andrew A Monte; Rachel Huddart; Kelly E Caudle; Evan D Kharasch; Andrea Gaedigk; Henry M Dunnenberger; J Steven Leeder; John T Callaghan; Caroline Flora Samer; Teri E Klein; Cyrine E Haidar; Sara L Van Driest; Gualberto Ruano; Katrin Sangkuhl; Larisa H Cavallari; Daniel J Müller; Cynthia A Prows; Mohamed Nagy; Andrew A Somogyi; Todd C Skaar Journal: Clin Pharmacol Ther Date: 2021-02-09 Impact factor: 6.903
Authors: D A Todd; J J Kellogg; E D Wallace; M Khin; L Flores-Bocanegra; R S Tanna; S McIntosh; H A Raja; T N Graf; S E Hemby; M F Paine; N H Oberlies; N B Cech Journal: Sci Rep Date: 2020-11-05 Impact factor: 4.379
Authors: Rob Hill; Alex Disney; Alex Conibear; Katy Sutcliffe; William Dewey; Stephen Husbands; Chris Bailey; Eamonn Kelly; Graeme Henderson Journal: Br J Pharmacol Date: 2018-05-14 Impact factor: 8.739